Project Grant R01CA296581
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$714K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
The National Cancer Institute (NCI) awarded a $2,679,816 Project Grant (CFDA 93.396 Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai. The 5-year grant, effective August 1, 2025, will support an integrated research program focused on understanding the role of mutant p53 proteins in tumor progression, invasion, and metastasis. The program consists of four interrelated projects that will use systematic studies, molecular mechanisms, and transcriptional regulation approaches...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $147,083 to the Icahn School of Medicine at Mount Sinai to conduct research on "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance." The goal is to study the epigenetic regulation and priming of key regulatory pathways in tumor-educated bone marrow myeloid progenitors, which contribute to immunosuppression and therapy...
This $505,270.00 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai to investigate the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer. The research aims to develop new therapeutic strategies, with a project period from September 30, 2025 to September 29, 2027. As a leading academic medical...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This federal Project Grant award for $538,553, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will support research to define the role of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The 5-year project, which commenced on April 1, 2025, will be conducted by the University...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This $507,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at the Icahn School of Medicine at Mount Sinai (ISMMS) to study the role of exosomes in promoting prostate cancer metastasis and resistance to androgen deprivation therapy. The 2-year grant, awarded on June 15, 2024, will enable ISMMS to conduct innovative biomedical research with the goal of advancing understanding and treatment of...
This federal Project Grant award of $633,750.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, aimed at understanding the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This 3-year research project, from August 1, 2025 to July 31, 2028, seeks to...